Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT 1 and MT 2 melatonin receptors. Ramelteon's halflife is longer than that of melatonin, being metabolized in the body to four main metabolites, M-I, M-II, M-III, and M-IV. M-II has an affinity to MT 1 and MT 2 of about one-tenth of the parent compound, but its concentration in the circulation exceeds that of ramelteon by more than an order of magnitude. Ramelteon is effective in decreasing latency to persistent sleep and increasing total sleep time in freely moving monkeys. A number of clinical studies have been undertaken to study the efficacy of ramelteon in subjects with chronic insomnia. In almost all of these studies, ramelteon, in various doses of 4, 8, or 16 mg most commonly, significantly reduced sleep latency and increased sleep duration. Its primary action in sleep promotion is not a generalized gamma-aminobutyric (GABA)-ergic central nervous system depression, but rather it acts as a melatonergic agonist in the suprachiasmatic nucleus (and at other central nervous system sites), from where downstream processes, including GABA-ergic effects, are controlled via the hypothalamic sleep switch. Unlike other commonly prescribed hypnotic drugs, ramelteon is not associated with next morning hangover effects or reductions in alertness, nor has it been shown to cause withdrawal symptoms.
INTRODUCTION
Melatonin, the major hormone secreted by the pineal gland, was first identified by Lerner in 1958. This hormone has a number of important physiological functions including regulation of circadian rhythms, sleep promotion and consolidation, 1 anti-oxidative defense, 2-4 immune regulation and aging, 5,6 control of reproductive activity, 7,8 and suppression of tumor growth. 9, 10 The secretion of melatonin is greatest during the dark hours of the night, an effect so consistently expressed that it is now considered to be the chemical signal indicating the length of darkness. 11 As the highest levels of melatonin secretion occur during the nighttime in diurnally active vertebrates, it has been suggested that melatonin has a crucial role in sleep promotion, at least in this group of organisms. Owing to its involvement in the regulation of circadian rhythms, any disruption in melatonin secretion may play an important part in the etiology of circadian rhythm sleep disorders (CRSD). This has consequently led to advocacy for exogenous melatonin use in the treatment of CRSD. [12] [13] [14] [15] [16] Melatonin is also being widely used as a natural supplement or, in its analog variants, as a drug for various sleep disorders, including the (self-) treatment of insomnia. [17] [18] [19] [20] 
MANAGEMENT OF INSOMNIA
Insomnia is one of the most frequently reported complaints in clinical practice and affects 30%-40% of the adult population. 21 It most commonly occurs in elderly individuals, 22, 23 in patients with depression, 24 and in those with dementia and neurodegenerative disorders. According to a National Sleep Foundation survey (USA), 75% of the adults in the USA have at least one symptom of a sleep disorder and 54% have one symptom related to insomnia. 25 Treatment for insomnia includes both nonpharmacologic and pharmacologic treatments. Selection of an appropriate antiinsomnia therapy is based upon a number of factors such as age, the nature of the disease, response to current medications, etc. A number of nonpharmacologic therapies including cognitive behavioral therapy, relaxation therapy, yoga, stimulus control therapy, and sleep-hygiene education have all been employed for treatment of insomnia and have been variously found effective in certain cases. 26, 27 Drugs such as triazolam or zolpidem that act as benzodiazepine receptor agonists (BzRAs) and that modulate gamma-aminobutyric A (GABA A ) receptor function in the brain are used widely for treating insomnia. 28 The antidepressant trazodone is also commonly prescribed for the condition. These drugs, however, have been linked to a number of side effects.
Benzodiazepines (BZDs) are associated with cognitive and memory impairment, 29 while trazodone has been shown to cause cardiac rhythm disturbances and orthostatic hypotension. 30 Drugs without these side effects would certainly benefit not only elderly individuals with insomnia but also a number of other patients with this condition.
Melatonin in Insomnia
Sleep disturbances, which are frequently observed in the elderly, have been related to low nocturnal melatonin production that is seen in most individuals of advanced age. 31 Melatonin's sleep-promoting activity has indeed been demonstrated both in animals and humans. Melatonin has been shown to reduce sleep onset latency (SOL) and to increase sleep efficiency when administered in the evening to healthy adults in doses ranging from 0.3 to 1 mg. 32, 33 Brain imaging studies of awake subjects have shown that melatonin modulates brain activity patterns to resemble those of actual sleep. 34 A number of double-blind, placebo-controlled studies have demonstrated that melatonin is suitable as a hypnotic drug.
In a study undertaken with 13 patients, ranging in age from 25 to 65 years, administration of 75 mg of melatonin for 7 days significantly increased the subjective report of total sleep time (TST) and daytime alertness when compared with placebo; 35 however, the dose of melatonin administered was high. In another study, a low dosage of melatonin was used. In this double-blind placebo-controlled study of 10 patients, administration of melatonin in 1 mg and 5 mg doses significantly improved the overall subjective quality of sleep and promoted an earlier onset of sleep. Rapid eye movement onset latency was also delayed in this study. 36 Melatonin administration (5 mg/fast-release tablets) was found to improve sleep quality in seven of 15 patients with insomnia who had been resistant to treatment with BZDs and zopiclone. 37 Although the exact reason for this difference is not known, melatonin levels in the cerebrospinal fluid of the third ventricle, which are nearly 20 times higher than those found in the circulation, were assumed to be responsible for the variations of melatonin's action in the brain. 53, 54 Despite the evidence of these cited reports on melatonin's hypnotic actions, its efficacy in promoting sleep efficiency has been questioned, especially as most of the results have shown only borderline significance or are otherwise difficult to evaluate because of methodological inconsistencies. 55 The poor outcomes concerning sleep efficiency or TST have been attributed to melatonin's short half-life (of less than 30 minutes) in the circulation. It has therefore been suggested that a melatonergic agonist with a longer half-life and, thus, an enhanced bioavailability, would saturate MT 1 and MT 2 receptors in the SCN more efficiently and for a longer duration of time. It has consequently been further suggested that such an agonist might be of greater benefit than melatonin in promoting sleep efficiency in patients with insomnia. 54
RAMELTON, A MELATONERGIC AGONIST WITH SLEEP PROMOTING PROPERTIES
TAK-375} is a novel melatonin receptor agonist that has been shown to be selective for MT 1 and MT 2 receptors, but without affinity for the melatonin-binding quinone reductase 2, previously called MT 3 . 56,57 Ramelteon has no affinity for GABA-ergic, dopaminergic, opioidergic, nor any other major CNS receptors, binding sites of neurotransmitters or neuropeptides, regulatory enzymes, or ion channels. 56,57 However, various additional nonmembrane-binding sites of melatonin remain to be tested. 58
Pharmacokinetics of Ramelteon
In-vitro binding studies have shown that ramelteon's affinity for MT 1 and MT 2 receptors is 3-16 times higher than that of melatonin itself. Although ramelteon has a relatively short half-life (1.2 hours), it is, however, substantially longer than that of melatonin. 56 When administered orally, ramelteon is absorbed rapidly in fasting conditions and reaches its peak concentration in plasma in 45 minutes, which ranges from 30 minutes to 1.5 hours.
The total absorption of this drug is 84%, but its total bioavailability is only 1.8%. After administration of the therapeutic dose (8 mg), the peak plasma concentration of ramelteon increases up to 57,000 pg/mL. 59 Ramelteon is metabolized by oxidation to hydroxyl and carbonyl derivatives and is eliminated within 96 hours after oral administration.
It is metabolized in humans to four metabolites: M-I, M-II, M-III, and M-IV. M-II is the major metabolite of ramelteon followed by M-IV, M-I, and M-III. M-II exhibits a selectivity for melatonin MT 1 and MT 2 receptors that is similar to that of the parent compound; however, it has an affinity of only 10% of that of ramelteon. 56 M-II attains plasma concentrations 20-100-fold (average about 30-fold) greater than that of the parent compound, 60 M-II, which is formed by the cytochrome P450 subform CYP1A2, and has a half-life of 2-4 hours in the circulation, a value that only partially explains the differences in concentration. Despite the lower receptor affinity, the considerably higher blood levels of M-II support the hypothesis that this metabolite should substantially contribute to ramelteon's overall activity, 60 and may enhance its sleeppromoting efficacy. Ramelteon clearance has often been shown to be significantly reduced in elderly subjects, an effect that is not significantly influenced by gender. In view of the extended persistence of M-II in the circulation, the pharmacokinetics of the drug should not be primarily judged on the basis of ramelteon clearance alone. This is one of the most unusual pharmacokinetic properties of ramelteon.
Ramelteon: Sleep-Promoting Actions in

Primate Studies
In a study conducted in young adult female monkeys (n=22) (Macaca fascicularis), cortical electroencephalography, electromyography, and electrooculography were recorded. 61 Individual monkeys received, at 6:00 PM, different doses of ramelteon (0.003, 0.03, and 0.3 mg/kg) and, correspondingly, other animals were treated at the same circadian phase with different doses of melatonin (0.3, 1, and 3 mg/kg). For comparison, zolpidem was also administered to other experimental groups (1, 3, 10, and 30 mg/kg). The study demonstrated that ramelteon, in doses of 0.03 and 0.3 mg/kg, was effective in reducing the time to sleep onset as compared with controls.
Ramelteon, in these two doses, also significantly increased the total duration of sleep. Melatonin (1 and 3 mg doses) also tended to increase the total duration of sleep, but without attaining statistical significance. Zolpidem, in none of the doses tested (1, 3, 10, and 30 mg/kg), had any effect on the latency to slow wave sleep, nor on TST. The investigators concluded that ramelteon reduced the SOL and increased sleep duration in freely moving monkeys without producing the side effects often seen with BzRAs. 61 In another study in monkeys, ramelteon did not promote physical dependence, 62 a finding of particular importance for judging the usefulness of the drug.
Ramelteon's Effects on Sleep: Clinical Studies
The efficacy, safety, and dose-response of ramelteon were evaluated by Erman et al. 63 Similarly, the group of patients with a screening TST less than 358 minutes showed greater improvements than did the group whose screening was greater than 358 minutes. 63 All ramelteon doses resulted in similar improvements suggesting that ramelteon promotes sleep in a manner that differs from that of other hypnotics.
More specifically, ramelteon activates MT 1 receptors in the SCN to attenuate the circadian wake- LPS was significantly reduced with ramelteon 8 mg (32.2 minutes) or 16 mg (28.9 minutes), when compared with placebo (47.9 minutes). These effects were maintained following 3-5 weeks (after ramelteon was discontinued).
Both doses of ramelteon also prolonged total duration of sleep. 66 In a related study involving a larger popu- DSPS is a CRSD in which SOL is delayed in some cases by as much as 2-6 hours. It is characterized by the chronic inability to fall asleep at the desired clock time. 74 Dahlitz et al. 75 reported that the administration of 5 mg mela- 
ADVERSE EFFECTS OF RAMELTEON AND SAFETY
The incidence of adverse effects of ramelteon, as inferred from subjects' complaints and neurologic parameters, has been reported to be similar to that of placebo. In a study by Erman et al. 63 the incidence of treatment-emergent adverse events ranged from 8.4% to 10.7% among the ramelteon groups and was 8.7% in the placebo group. The most commonly reported adverse events were headache, somnolence, dizziness, and sore throat. Ramelteon was found to be well tolerated and showed no significant next-day morning psychomotor, memory, or cognitive effects. 67, 77, 78 this regard have been discussed elsewhere 58, 80, 81 and may become particularly relevant for longterm treatment with the drug.
It should be noted that in May 2008 the EMEA declined to grant marketing authorization for ramel-teon. Following this, Takeda
Pharmaceuticals requested a re-examination of the opinion, which was under review at the time of the application withdrawal by the company, based on its current plan to extend the clinical program to address EMEA's questions regarding the medicine's risk-benefit profile.
Some Pharmacodynamic Considerations
Concerning Ramelteon
Taken together, the evidence reviewed above suggests generally that ramelteon, like mela- 
CONCLUSIONS
Ramelteon has been reported to be a safe hypnotic drug for clinical use in chronic primary insomnia. Clinical studies have shown that ramelteon reduces the SOL and increases TST. During treatments lasting several weeks, the incidence of adverse effects with ramelteon has been reported to be similar to that of placebo.
Ramelteon administration has been shown to be free of other undesired effects such as next day hangover, memory impairment, psychomotor retardation, or cognitive impairment. The hypnotic action of ramelteon is attributed to its effect on melatonergic MT 1 and MT 2 receptors present in the SCN. It has been also effective in causing phase advances of sleep-wake rhythms in humans, and thus has potential therapeutic value not only in primary insomnia but also in CRSD. No study is available comparing ramelteon versus melatonin in their efficacy.
Other melatonergic agonists, such as agomelatine and tasimelteon, are now on the market or are in the process of being approved by the FDA or EMEA. Moreover, a slow-release preparation of melatonin has just been approved by EMEA for use in elderly patients with sleep disorders.
A last important point to be considered is that melatonin-like compounds generally display a modest sleep-inducing effect, quite mild as compared with BZP. Certainly because of the long time in the market and the lack of new alternatives for the treatment of insomnia, the preconception that the consumer has of a sleep pill is that of a strong sleep inducer, something that the melatonin family of compounds will never accomplish. Therefore, a very important educational goal is to change this view on the lack of negative effects (addiction, dependence, etc) that melatonin analogs have in the face of the well-known complications of BZP. 89
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